Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO)
- 252 Downloads
Fatigue is one of the most distressing symptoms of cancer patients. Its characteristics and impact on quality of life have not been fully explored and treatment of cancer-related fatigue in Italian oncological centers has not been codified.
A cross-sectional study was carried out on all patients attending for any reason the 24 participating centers in two non-consecutive days. Patients with fatigue filled out the Brief Fatigue Inventory (BFI) questionnaire and reported any pharmacological or non-pharmacological treatment for fatigue.
From October 2014 to May 2015, 1394 cancer patients agreed to participate in the study. Fatigue was referred by 866 (62.1%) of patients; its duration was > 4 months in 441 patients (50.9%). In the investigators’ opinion, the most important (probable or almost sure) determinants of fatigue were reduced physical activity (271 patients), anxiety (149), pain (131), insomnia (125), anemia (123), and depression (123). Fatigue of moderate/severe intensity was reported by 43%/29.2% of patients, while usual fatigue in the last 24 h by 45%/33.1%, and the worst fatigue in the last 24 h by 33%/54.8%, respectively. Concerning the impact on quality of life, fatigue interfered moderately/severely with general activity in 30.8%/38.6% of patients, with mood in 26.1%/32.8%, with the ability to work in 27.9%/35.6%, with normal work in 26.7%/38.9%, with relationships with others in 21%/23.4% and with the ability to amuse themselves in 22.2%/33.1%. Only 117/866 patients (13.5%) received a pharmacological treatment represented by a corticosteroid in 101 patients (86.3%) while 188 patients (21.7%) received a non-pharmacological treatment such as physical exercise (120 patients, 63.8%) and various alimentary supplements (52 patients, 27.6%).
Cancer-related fatigue is frequently reported by oncological patients; its intensity and impact on quality of life is relevant.
KeywordsCancer-related fatigue Characteristics of fatigue Pharmacological treatment Non-pharmacological treatment
Other investigators are the following: Andrea Sbrana, Gianna Musettini, Azzurra Farnesi, Francesco Spina, Paola Matteucci, Paolo Bossi, Elisa Minenza, Camilla Di Nunzio, Elena Orlandi, Claudia Biasini, Alessandro Inno, Monica Turazza, Fabiana Marchetti, Domenica Pellegrini, Simona Gasparro, Daniele Alesini, Rossana De Feudis, Teresa Gasparre, Michele Altieri, Elisabetta Cretella, Alessandro Marabese, Maurizio Valeriani, Claudia Scaringi, Salvatore Artale, Lucia Barbarini, Eleonora Capovilla, Silvia Tessarin, Giovanni Battista Ivaldi, Ilaria Meaglia, Evaristo Maiello, Chiara Parati, Saverio Cinieri, Luigi Coltelli, Angela S. Ribecco, Emanuela Romagnoli, Antonio Ardizzoia, Paolo Tralongo, Amalia Falzetta, Elena Bandieri, Marco Danova.
Compliance with ethical standards
Conflict of interest
Fausto Roila declares no conflict of interest. Fausto Roila declares to have full control of all primary data and he agrees to allow the journal to review the data if requested.
- 1.(2017) NCCN Clinical practice guidelines in oncology cancer-related fatigue. Version 2. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx
- 2.Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, Schnipper HH, Lacchetti C, Ligibel JA, Lyman GH, Ogaily MS, Pirl WF, Jacobsen PB, American Society of Clinical Oncology (2014) Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology Clinical Practice Guideline Adaption. J Clin Oncol 32:1840–1850CrossRefGoogle Scholar
- 3.Horneber M, Fischer I, Dimeo F et al (2012) Cancer-related fatigue: epidemiology, pathogenesis, diagnosis and treatment. Dtsch Arztebl Int 109:161–167Google Scholar
- 13.Bourmaud A, Anota A, Moncharmont C, Tinquaut F, Oriol M, Trillet-Lenoir V, Bajard A, Parnalland S, Rotonda C, Bonnetain F, Pérol D, Chauvin F (2017) Cancer-related fatigue management: evaluation of a patient education program with a large-scale randomized controlled trial, the PEPs fatigue study. Br J Cancer 116:849–858CrossRefGoogle Scholar
- 14.Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, Mohr D, Palesh OG, Peppone LJ, Piper BF, Scarpato J, Smith T, Sprod LK, Miller SM (2017) Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 3:961–968CrossRefGoogle Scholar
- 20.Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scherr SL, Portenoy RK (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34(3 Suppl 2):4–12Google Scholar